6838 Stock Overview
A clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Formosa Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$37.65 |
| 52 Week High | NT$66.90 |
| 52 Week Low | NT$36.90 |
| Beta | 1.09 |
| 1 Month Change | -3.21% |
| 3 Month Change | -15.58% |
| 1 Year Change | -24.85% |
| 3 Year Change | 9.77% |
| 5 Year Change | n/a |
| Change since IPO | -32.77% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6838 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -3.5% | -0.01% | -2.1% |
| 1Y | -24.9% | -2.7% | 25.6% |
Return vs Industry: 6838 underperformed the TW Pharmaceuticals industry which returned -2.7% over the past year.
Return vs Market: 6838 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility
| 6838 volatility | |
|---|---|
| 6838 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 3.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in TW Market | 7.8% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6838 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6838's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | n/a | Erick Co | www.formosapharma.com |
Formosa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in developing drug candidates for ophthalmology, oncology, and anti-infectives in Taiwan. It is involved in developing APP13007 that is in Phase III clinical trial for the treatment of post-operative pain and inflammatory eye conditions; TSY-0110, an antibody-drug conjugate; and TSY-0210, an antibiotic for drug resistant infections. The company also develops APP13002 to treat infectious eye diseases, such as conjunctivitis, keratitis, blepharitis, and meibomian gland dysfunction; and MPT0E028, a novel pan- histone deacetylase inhibitor for solid tumors, such as hepatomas and colorectal cancer.
Formosa Pharmaceuticals, Inc. Fundamentals Summary
| 6838 fundamental statistics | |
|---|---|
| Market cap | NT$5.68b |
| Earnings (TTM) | -NT$204.94m |
| Revenue (TTM) | NT$137.46m |
41.4x
P/S Ratio-27.7x
P/E RatioIs 6838 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6838 income statement (TTM) | |
|---|---|
| Revenue | NT$137.46m |
| Cost of Revenue | NT$21.13m |
| Gross Profit | NT$116.33m |
| Other Expenses | NT$321.27m |
| Earnings | -NT$204.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.36 |
| Gross Margin | 84.63% |
| Net Profit Margin | -149.09% |
| Debt/Equity Ratio | 0% |
How did 6838 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 12:42 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Formosa Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|